Immunization with a Single Major Histocompatibility Complex Class I-restricted Cytotoxic T-lymphocyte Recognition Epitope of Herpes Simplex Virus Type 2 Confers Protective Immunity

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1998 Nov 13

PMID 9811690

Citations 52

Authors

J E Blaney Jr

E Nobusawa

M A Brehm

R H Bonneau

L M Mylin

T M Fu

Y Kawaoka

S S Tevethia

Affiliations

Soon will be listed here.

Abstract

We have evaluated the potential of conferring protective immunity to herpes simplex virus type 2 (HSV-2) by selectively inducing an HSV-specific CD8(+) cytotoxic T-lymphocyte (CTL) response directed against a single major histocompatibility complex class I-restricted CTL recognition epitope. We generated a recombinant vaccinia virus (rVV-ES-gB498-505) which expresses the H-2Kb-restricted, HSV-1/2-cross-reactive CTL recognition epitope, HSV glycoprotein B residues 498 to 505 (SSIEFARL) (gB498-505), fused to the adenovirus type 5 E3/19K endoplasmic reticulum insertion sequence (ES). Mucosal immunization of C57BL/6 mice with this recombinant vaccinia virus induced both a primary CTL response in the draining lymph nodes and a splenic memory CTL response directed against HSV gB498-505. To determine the ability of the gB498-505-specific memory CTL response to provide protection from HSV infection, immunized mice were challenged with a lethal dose of HSV-2 strain 186 by the intranasal (i.n.) route. Development of the gB498-505-specific CTL response conferred resistance in 60 to 75% of mice challenged with a lethal dose of HSV-2 and significantly reduced the levels of infectious virus in the brains and trigeminal ganglia of challenged mice. Finally, i.n. immunization of C57BL/6 mice with either a recombinant influenza virus or a recombinant vaccinia virus expressing HSV gB498-505 without the ES was also demonstrated to induce an HSV-specific CTL response and provide protection from HSV infection. This finding confirms that the induction of an HSV-specific CTL response directed against a single epitope is sufficient for conferring protective immunity to HSV. Our findings support the role of CD8(+) T cells in the control of HSV infection of the central nervous system and suggest the potential importance of eliciting HSV-specific mucosal CD8(+) CTL in HSV vaccine design.

Citing Articles

Modified Vaccinia Virus Ankara Can Induce Optimal CD8 T Cell Responses to Directly Primed Antigens Depending on Vaccine Design.

Wong Y, Croft S, Smith S, Lin L, Cukalac T, La Gruta N J Virol. 2019; 93(21).

PMID: 31375596 PMC: 6803277. DOI: 10.1128/JVI.01154-19.

Blockade of LAG-3 Immune Checkpoint Combined With Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-viral CD8 T Cells and Protect Against Recurrent Ocular Herpes Simplex Infection and Disease.

Roy S, Coulon P, Srivastava R, Vahed H, Kim G, Walia S Front Immunol. 2019; 9:2922.

PMID: 30619285 PMC: 6304367. DOI: 10.3389/fimmu.2018.02922.

Phenotypic and Functional Signatures of Herpes Simplex Virus-Specific Effector Memory CD73CD45RACCR7CD8 T and CD73CD45RACCR7CD8 T Cells Are Associated with Asymptomatic Ocular Herpes.

Srivastava R, Coulon P, Roy S, Chilukuri S, Garg S, BenMohamed L J Immunol. 2018; 201(8):2315-2330.

PMID: 30201808 PMC: 6195422. DOI: 10.4049/jimmunol.1800725.

Increasing antigen presentation on HSV-1-infected cells increases lesion size but does not alter neural infection or latency.

Russell T, Velusamy T, Tseng Y, Tscharke D J Gen Virol. 2018; 99(5):682-692.

PMID: 29620508 PMC: 5994700. DOI: 10.1099/jgv.0.001059.

Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8 T and T Cell Responses against Herpesvirus Infection and Disease.

Lopes P, Todorov G, Pham T, Nesburn A, Bahraoui E, BenMohamed L J Virol. 2018; 92(8).

PMID: 29437976 PMC: 5874417. DOI: 10.1128/JVI.02156-17.

References

Castrucci M, Hou S, Doherty P, Kawaoka Y . Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. J Virol. 1994; 68(6):3486-90. PMC: 236851. DOI: 10.1128/JVI.68.6.3486-3490.1994. View

Lawson C, Bennink J, Restifo N, Yewdell J, Murphy B . Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol. 1994; 68(6):3505-11. PMC: 236854. DOI: 10.1128/JVI.68.6.3505-3511.1994. View

Smith P, Wolcott R, Chervenak R, Jennings S . Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma (IFN-gamma). Virology. 1994; 202(1):76-88. DOI: 10.1006/viro.1994.1324. View

McLean C, Erturk M, Jennings R, Challanain D, Minson A, Duncan I . Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis. 1994; 170(5):1100-9. DOI: 10.1093/infdis/170.5.1100. View

Burke R, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G . The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis. 1994; 170(5):1110-9. DOI: 10.1093/infdis/170.5.1110. View

Snyder H, Yewdell J, Bennink J . Trimming of antigenic peptides in an early secretory compartment. J Exp Med. 1994; 180(6):2389-94. PMC: 2191784. DOI: 10.1084/jem.180.6.2389. View

Salvucci L, Bonneau R, Tevethia S . Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes. J Virol. 1995; 69(2):1122-31. PMC: 188685. DOI: 10.1128/JVI.69.2.1122-1131.1995. View

Drummond C, Eglin R, Esiri M . Herpes simplex virus encephalitis in a mouse model: PCR evidence for CNS latency following acute infection. J Neurol Sci. 1994; 127(2):159-63. DOI: 10.1016/0022-510x(94)90068-x. View

Manickan E, Rouse R, Yu Z, Wire W, Rouse B . Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. J Immunol. 1995; 155(1):259-65. View

10.

Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, Gheysen D . Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J Virol. 1995; 69(8):4711-6. PMC: 189277. DOI: 10.1128/JVI.69.8.4711-4716.1995. View

11.

Posavad C, Koelle D, Shaughnessy M, Corey L . Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A. 1997; 94(19):10289-94. PMC: 23355. DOI: 10.1073/pnas.94.19.10289. View

12.

Fu T, Mylin L, Schell T, Bacik I, Russ G, Yewdell J . An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol. 1998; 72(2):1469-81. PMC: 124628. DOI: 10.1128/JVI.72.2.1469-1481.1998. View

13.

Morrison L, Da Costa X, Knipe D . Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology. 1998; 243(1):178-87. DOI: 10.1006/viro.1998.9047. View

14.

Posavad C, Koelle D, Corey L . Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nat Med. 1998; 4(4):381-2. DOI: 10.1038/nm0498-381. View

15.

Rodriguez F, An L, Harkins S, Zhang J, Yokoyama M, Widera G . DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol. 1998; 72(6):5174-81. PMC: 110091. DOI: 10.1128/JVI.72.6.5174-5181.1998. View

16.

Kunkel T, Roberts J, Zakour R . Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987; 154:367-82. DOI: 10.1016/0076-6879(87)54085-x. View

17.

Mylin L, Deckhut A, Bonneau R, Kierstead T, Tevethia M, Simmons D . Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen. Virology. 1995; 208(1):159-72. DOI: 10.1006/viro.1995.1139. View

18.

Rhim J, Cho H, HUEBNER R . Non-producer human cells induced by murine sarcoma virus. Int J Cancer. 1975; 15(1):23-9. DOI: 10.1002/ijc.2910150104. View

19.

Pretell J, Greenfield R, Tevethia S . Biology of simian virus 40 (SV40) transplantation antigen (TrAg). V In vitro demonstration of SV40 TrAg in SV40 infected nonpermissive mouse cells by the lymphocyte mediated cytotoxicity assay. Virology. 1979; 97(1):32-41. DOI: 10.1016/0042-6822(79)90370-2. View

20.

Lawman M, Rouse B, Courtney R, Walker R . Cell-mediated immunity against herpes simplex induction of cytotoxic T lymphocytes. Infect Immun. 1980; 27(1):133-9. PMC: 550735. DOI: 10.1128/iai.27.1.133-139.1980. View